Several years ago, a little-known drug named Ozempic — previously used only to treat diabetes — emerged as a promising new ...

Shares of Novo Nordisk ( NVO 4.37%) were moving higher on Wednesday. The company's stock gained 4.9% as of 1:50 p.m. ET, but ...

The GLP-1 drug, exenatide, has no positive impact on the movement, symptoms or brain imaging of people with Parkinson's, ...

A final-stage study has found that exenatide, a GLP-1 drug used to treat Type 2 diabetes, showed no benefit in slowing the progression of Parkinson's disease. The 96-week trial, published in The ...

The GLP-1 compound drug sold by Hims and Hers is not approved by the FDA and its Super Bowl ad fails to list any risks ...

On the company’s earnings call yesterday, Chief Scientific Officer Dan Skrovronsky said it plans to start a Phase 3 trial of its GLP-1 pill, orforglipron, in hypertension. Lilly also plans to ...

GLP-1 medications such as Ozempic and Wegovy have had a transformative effect for those struggling with weight loss. Many ...

The GLP-1 drug, exenatide, has no positive impact on the movement, symptoms or brain imaging of people with Parkinson's, finds a new study led by UCL researchers.

For people with diabetes, the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with a reduced risk for certain disorders and conditions.